Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids

Journal of Computer-Aided Molecular Design

Volumn 28, Issue 7, 2014, Pages 751-763

  Santoshi, Seneha ^a   Naik, Pradeep K ^a,b  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Binding affinity; Isotypes; MD simulation; Noscapinoids; Tubulin

Indexed keywords

CANCER CELLS; CELL PROLIFERATION;

BINDING AFFINITIES; CELLULAR PROLIFERATIONS; DYNAMIC INSTABILITY; HETERODIMERS; ISOTYPE; MD SIMULATION; MOLECULAR INSIGHTS; NOSCAPINE; NOSCAPINOID; TUBULIN;

BINDING ENERGY;

ALPHABETA TUBULIN; BETA TUBULIN; HETERODIMER; NOSCAPINE; UNCLASSIFIED DRUG; 9-AMINO-ALPHA-NOSCAPINE; COLCHICINE; ISOPROTEIN; PROTEIN BINDING; TUBULIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DENSITY FUNCTIONAL THEORY; DRUG BINDING SITE; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; PROTEIN MULTIMERIZATION;

BINDING SITES; CELL PROLIFERATION; COLCHICINE; HUMANS; NEOPLASMS; NOSCAPINE; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; TUBULIN;

EID: 84904393934     PISSN: 0920654X     EISSN: 15734951     Source Type: Journal    
DOI: 10.1007/s10822-014-9756-9     Document Type: Article

References (53)

1. Stanton RA, Gernert KM, Nettles JH, Aneja R (2011) Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 31(3):443-481
2. Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC (2003) Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci 24(7):361-365 (Pubitemid 37315528)
3. Downing KH (2000) Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 16:89-111
4. Alam MA, Naik PK (2009) Molecular modelling evaluation of the cytotoxic activity of podophyllotoxin analogues. J Comput Aided Mol Des 23:209-225
5. Luduena RF (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178:207-275
6. Banerjee A, Luduena RF (1992) Kinetics of colchicine binding to purified beta tubulin isotypes from bovine brain. J Biol Chem 267:13335-13339
7. Mozzetti S, Ferlini C, Concolino P et al (2005) Class III B-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11:298-305 (Pubitemid 40075808)
8. Joshua A, McCarroll Gan PP, Liu M, Kavallaris M (2010) βIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Clin Cancer Res 70(12):4995-5003
9. Nicoletti MI, Valoti G, Giannakakou P et al (2001) Expression of β-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 7:2912-2922 (Pubitemid 32911402)
10. Zhang Y, Yang H, Liu J et al (2013) High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncol Lett 6:220-226
11. Huzil JT, Luduena RF, Tuszynski J (2006) Comparative modelling of human beta-tubulin isotypes and implications for drug binding. Nanotechnology 17:S90-S100 (Pubitemid 43190484)
12. Mane JY, Klobukowski MJ, Huzil T, Tuszynski J (2008) Free energy calculations on the binding of colchicine and its derivatives with the α/β-tubulin isoforms. J Chem Inf Model 48(9):1824-1832
13. Gan PP, Pasquier E, Kavallaris M (2000) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67:9356-9363
14. Kim YS, Tseng CY, Mane JY, Winter P, Johnson L, Huzil T, Izbicka E, Luduena RF, Tuszynski J (2010) Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives. Mol Cancer 9:131
15. Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WE, Wohlschlaeger J (2012) βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer. Br J Cancer 107:823-830
16. Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, Petros J, Joshi HC (1998) Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 95:1601-1606 (Pubitemid 28103439)
17. Joshi HC, Salil A, Bughani U, Naik PK (2010) Noscapinoids: a new class of anticancer drugs demand bio-technological intervention. In: Arora R (ed) Medicinal plant biotechnology, CAB e-Books CABI (H ISBN 9781845936785)
18. Mahmoudian M, Rahimi-Moghaddam P (2009) The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov 4(1):92-97
19. Landen J, Lang WR, McMahon SJ, Rusan NM, Yvon AM, Adams AW, Sorcinelli MD, Campbell R, Bonaccorsi P, Ansel JC, Archer DR, Wadsworth P, Armstrong CA, Joshi HC (2002) Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma. Cancer Res 62:4109-4114 (Pubitemid 34791082)
20. Zhou J, Panda D, Landen JW, Wilson L, Joshi HC (2002) Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 277:17200-17208 (Pubitemid 34967753)
21. Aneja R, Vangapandu SN, Lopus M, Viswesarappa VG, Dhiman N, Verma A, Chandra R, Panda D, Joshi HC (2006) Synthesis of microtubule-interfering halogenated noscapine analogues that perturb mitosis in cancer cells followed by cell death. Biochem Pharmacol 72:415-426 (Pubitemid 44061746)
22. Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, Joshi HC (2003) Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 63:799-807 (Pubitemid 36368986)
23. Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC (2006) Development of a novel nitro-derivative of Noscapine for the potential treatment of drug-resistant ovarian cancer and Tcell lymphoma. Mol Pharmacol 69:1801-1809 (Pubitemid 43894296)
24. Naik PK, Chatterji BP, Vangapandu SN, Aneja R, Chandra R, Kanteveri S, Joshi HC (2011) Rational design synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoids. J Comput Aided Drug Des 25:443-454
25. 2-terminl kinase-mediated apoptosis in response to noscapine. J Biol Chem 277(42):39777-39785
26. Santoshi S, Naik PK, Joshi HC (2011) Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids. J Biomol Screen 16:1047-1058
27. Manchukonda NK, Naik PK, Santoshi S, Lopus M, Joseph S, Sridhar B, Kantevari S (2013) Rational design synthesis and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents. PLoS ONE 8(10):77970
28. Naik PK, Santoshi S, Rai A, Joshi HC (2011) Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site. J Mol Graph Model 29:947-955
29. Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95-98
30. Berendsen HJC, Spoel VD, Drunen VR (1995) GROMACS: a message passing parallel molecular dynamics implementation. Comput Phys Commun 91:43-56
31. Daren T, York D, Pedersen L (1993) Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems. J Chem Phys 98:10089-10092
32. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18:1463-1472 (Pubitemid 127637344)
33. Laskowski RA, MacArthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J App Crystal 26:283-291
34. Ramachandran GN, Ramakrishnan C, Sasisekharan V (1963) Stereochemistry of polypeptide chain configurations. J Mol Biol 7:95-99
35. Colovos C, Yeates TO (1993) Verification of protein structures: patterns of non-bonded atomic interactions. Protein Sci 2:1511-1519 (Pubitemid 23262844)
36. Eisenberg D, Luthy R, Bowie JU (1997) VERIFY3D: assessment 694 of protein models with three-dimensional profiles. Methods Enzymol 277:396-404
37. Lee C, Yang W, Parr RG (1988) Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 37:785-789
38. Becke AD (1993) A new mixing of Hartree-Fock and local density-functional theories. J Chem Phys 98:1372-1377
39. Binkley JS, Pople JA, Hehre WJ (1980) Self-consistent molecular orbital methods 21 small split-valence basis sets for first-row elements. J Am Chem Soc 102:939-947
40. Gordon MS, Binkley JS, Pople JA, Pietro WJ, Hehre WJ (1982) Self-consistent molecular-orbital methods 22 small split-valence basis sets for second-row elements. J Am Chem Soc 104:2797-2803
41. Pietro WJ, Francl MM, Hehre WJ, Defrees DJ, Pople JA, Binkley JS (1982) Self-consistent molecular orbital methods 24 supplemented small split-valence basis sets for second-row elements. J Am Chem Soc 104:5039-5048
42. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid accurate docking and scoring 1 method and assessment of docking accuracy. J Med Chem 47:1739-1749 (Pubitemid 38380917)
43. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid accurate docking and scoring 2 enrichment factors in database screening. J Med Chem 47:1750-1759 (Pubitemid 38380918)
44. Case DA, Walker RC et al (2010) AMBER 11. University of California, San Francisco
45. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA (1995) A second generation force field for the simulation of proteins nucleic acids and organic molecules. J Am Chem Soc 117:5179-5197
46. Wang JM, Wolf RM, Caldwell JW, Kollamn PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157-1174
47. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23:327-341
48. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Protein 65:712-725 (Pubitemid 44583220)
49. Berendsen HJC, Postma JP, van Gunsteren WF, DiNola A, Haak JR (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 81:3684-3691
50. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33:889-897 (Pubitemid 32056774)
51. Shen XL, Kamimura MT, Wei J, Gao QZ (2012) Computer-aided de novo ligand design and docking/molecular dynamics study of vitamin D receptor agonists. J Mol Model 18:203-212
52. Niu X, Gao X, Wang H, Wang X, Wang S (2013) Insight into the dynamic interaction between different flavonoids and bovine serum albumin using molecular dynamics simulations and free energy calculations. J Mol Model 19:1039-1047
53. Guo J, Wang X, Sun H, Liu H, Yao X (2012) T he molecular basis of IGF-II/IGF2R recognition: acombined molecular dynamics simulation free-energy calculation and computational alanine scanning study. J Mol Model 18:1421-1430